6 research outputs found
Serum-Soluble CD163 Levels as a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma Treated with Chemoimmunotherapy
The majority of patients with Diffuse Large B-cell Lymphoma (DLBCL) will respond to first-line treatment and be cured. However, the disease is heterogeneous, and biomarkers able to discriminate patients with suboptimal prognosis are needed. M2 CD163-positive tumor-associated macrophages (TAMs) were shown to be implicated in DLBCL disease activity regulation. Serum-soluble CD163 (sCD163) functions as a scavenger receptor for haptoglobin–hemoglobin complexes and is mostly expressed by monocytes and macrophages. Its levels are used to determine macrophage activation. We aimed to determine serum sCD163 in a sample of DLBCL patients and study eventual correlations with parameters of disease activity or survival. Serum sCD163 levels were measured in 40 frozen sera from patients diagnosed with DLBCL and 30 healthy individuals (HIs) using an enzyme-linked immunosorbent assay (ELISA). Statistical analyses were performed using SPSS version 28. The results showed that patients who achieved complete response after standard-of-care immunochemotherapy and were alive and disease-free after 12 months of follow-up but had elevated sCD163 levels (above median) at diagnosis presented a significantly worse overall survival compared to those with initial serum sCD163 levels below the median (p = 0.03). Consequently, serum sCD163 levels in patients with DLBCL may constitute a marker of long-term response to chemoimmunotherapy
Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis
Background/Aim: Hematological malignancies are frequently complicated by
secondary immunodeficiency (SID). Immunoglobulin replacement with
intravenous gamma globulins (IVIg) reduces infection incidence,
antibiotics’ need and hospitalization days in these patients.
Facilitated subcutaneous immunoglobulin replacement (fSCIg) has been
studied in primary immunodeficiency patients and is equally efficacious
with several advantages (self-administration, same bioavailability, long
infusion intervals, fewer adverse drug reactions). fSCIg has been less
extensively studied in SID. We present our retrospective single-center
data of fSCIg administration to hematological patients with SID,
focusing on efficacy and safety issues. Patients and Methods: Overall,
33 hematological patients with hypogammaglobulinemia were treated with
fSCIg according to ESMO 2015 guidelines, between mid-October 2015 and
mid-January 2018 in our Department. Results: The infection rate was very
low (18.1%). Shorter infusion intervals further reduced it. ADRs were
rare (9%) and mild (grade 1). fSCIg managed to reduce the everyday
nursery/hospital burden of our tertiary hospital. Conclusion: fSCIg
compares favorably to IVIg replacement in SID patients